Masimo (MASI) Stock Price

Masimo Price

NASDAQ·CLOSED
179.95USD
Market closed

Over the last 19 years Masimo grew revenue by 10.6% annually, reaching 1.53 B USD. Earnings per share have grown at 1.5% per year over the last 17 years. For Masimo, the net margin of -9.9% is down versus 18.5% a few years ago. At today's price the dividend yield works out to roughly 0.56%. The payout ratio is around 93% of earnings.

Masimo stock price

Volume
Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Masimo over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Masimo stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Masimo's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Masimo Stock Price History
DateMasimo Price
Access this data via the Eulerpool API

Masimo Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
224.3 M USD
46.4 M USD
61.8 M USD
Jan 1, 2007
256.3 M USD
68.4 M USD
23.1 M USD
Jan 1, 2008
307.1 M USD
72.1 M USD
31.9 M USD
Jan 1, 2009
349.1 M USD
82.5 M USD
53.2 M USD
Jan 1, 2010
405.4 M USD
90.2 M USD
73.5 M USD
Jan 1, 2011
439 M USD
101.2 M USD
63.7 M USD
Jan 1, 2012
493.2 M USD
85.2 M USD
62.3 M USD
Jan 1, 2013
547.2 M USD
87.7 M USD
58.4 M USD
Jan 1, 2014
586.6 M USD
93.2 M USD
72.5 M USD
Jan 1, 2015
630.1 M USD
100.7 M USD
83.3 M USD
Jan 1, 2016
712.9 M USD
165.9 M USD
311.1 M USD
Jan 1, 2017
790.2 M USD
183.8 M USD
124.8 M USD
Jan 1, 2018
858.3 M USD
208.4 M USD
193.5 M USD
Jan 1, 2019
937.8 M USD
221.2 M USD
196.2 M USD
Jan 1, 2020
1.14 B USD
255.3 M USD
240.3 M USD

Masimo Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 7, 2026, 4:34 AM
 
REVENUE (B USD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B USD)
NET INCOME (M USD)
NET INCOME GROWTH (%)
DIV. (USD)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
20222023202420252026e2027e2028e2029e
2.041.281.41.531.661.781.922.01
64.25-37.359.419.398.657.67.45.11
51.996056.9261.935752.9749.3246.92
1.060.770.790.950.950.950.950.95
14381-304-151322361406406
-37.55-43.36-475.31-50.33-313.2512.1112.47
----8.39.3210.46-
12.2912.23
55.254.153.353.653.653.653.653.6
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Masimo generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Masimo retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Masimo's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Masimo has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Masimo's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Masimo stock margins

The Masimo margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Masimo. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Masimo.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
72.54 %
20.69 %
27.55 %
Jan 1, 2007
71.28 %
26.69 %
9.01 %
Jan 1, 2008
70.86 %
23.48 %
10.39 %
Jan 1, 2009
71.27 %
23.63 %
15.24 %
Jan 1, 2010
70.45 %
22.25 %
18.13 %
Jan 1, 2011
66.99 %
23.05 %
14.51 %
Jan 1, 2012
66.16 %
17.27 %
12.63 %
Jan 1, 2013
65.57 %
16.03 %
10.67 %
Jan 1, 2014
66.62 %
15.89 %
12.36 %
Jan 1, 2015
65.07 %
15.98 %
13.22 %
Jan 1, 2016
67.09 %
23.27 %
43.64 %
Jan 1, 2017
66.06 %
23.26 %
15.79 %
Jan 1, 2018
66.98 %
24.28 %
22.54 %
Jan 1, 2019
67.09 %
23.59 %
20.92 %
Jan 1, 2020
64.97 %
22.32 %
21.01 %

Masimo Stock Revenue, EBIT, Earnings per Share

The Masimo earnings per share therefore indicates how much revenue Masimo has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
4.25 USD
0.88 USD
1.17 USD
Jan 1, 2007
4.29 USD
1.14 USD
0.39 USD
Jan 1, 2008
5.1 USD
1.2 USD
0.53 USD
Jan 1, 2009
5.8 USD
1.37 USD
0.88 USD
Jan 1, 2010
6.69 USD
1.49 USD
1.21 USD
Jan 1, 2011
7.22 USD
1.66 USD
1.05 USD
Jan 1, 2012
8.45 USD
1.46 USD
1.07 USD
Jan 1, 2013
9.52 USD
1.53 USD
1.02 USD
Jan 1, 2014
10.55 USD
1.68 USD
1.3 USD
Jan 1, 2015
11.73 USD
1.88 USD
1.55 USD
Jan 1, 2016
13.4 USD
3.12 USD
5.85 USD
Jan 1, 2017
14.14 USD
3.29 USD
2.23 USD
Jan 1, 2018
15.33 USD
3.72 USD
3.46 USD
Jan 1, 2019
16.42 USD
3.87 USD
3.44 USD
Jan 1, 2020
19.72 USD
4.4 USD
4.14 USD

Masimo business model & stock analysis

Masimo Corporation is an American medical technology company based in Irvine, California. The company was founded in 1989 by Professor Joe Kiani, who is still the chairman and CEO of the company today. With innovative products and advanced technology, Masimo aims to optimize medical diagnostic and treatment procedures to improve patient care. The business model of Masimo Corp focuses on developing and marketing products and solutions for patient monitoring and treatment in hospitals, intensive care facilities, and outpatient clinics. The company relies on high levels of innovation and collaboration with physicians, scientists, and other experts. The goal is to improve existing medical procedures, explore new applications for the technology, and optimize patient care. Masimo Corp's products are divided into different divisions that focus on various aspects of medical care. One example is the "Patient Monitoring" division, which offers various monitoring systems for vital signs such as respiration, pulse, and oxygen saturation. This includes products like the Rad-67 pulse oximeter or the Root patient monitor, which continuously monitor patients during treatment to enhance safety and effectiveness. Another division is "Anesthesia and Sedation," which focuses on solutions for anesthesiologists and intensive care specialists. Masimo Corp offers products such as the SedLine brain monitor or the EMMA main gas monitor, which enable physicians to control anesthesia depth more precisely and reduce the risk of complications. In addition to patient monitoring systems, Masimo Corp also provides solutions for neonatal care. The "Neonatal Care" division includes products like the Masimo Radical-7 pulse oximeter for monitoring premature infants or the Pronto-7 pulse oximeter for fast and accurate monitoring of newborns in the delivery room. Furthermore, Masimo Corp has developed products for monitoring surgical patients. The "Surgical and Minimally Invasive Monitoring" division, for example, offers the MOC-9 monitoring system for precise monitoring of hemodynamics during surgery. A unique product of Masimo Corp is also the Masimo SET sensor, which provides more accurate and reliable measurement of blood oxygen saturation than traditional pulse oximeter sensors. The company has filed over 100 patents worldwide for this technology and has been recognized with numerous awards and accolades. In summary, Masimo Corp is an innovative company specializing in improving medical care through the development and marketing of products for patient monitoring and treatment. With its state-of-the-art technologies and collaboration with experts in medical research, Masimo Corp sets standards for patient safety and treatment effectiveness.

Masimo SWOT Analysis

Strengths

Masimo Corp has several key strengths that contribute to its success in the market. Firstly, the company is known for its innovative and advanced medical monitoring technologies, which provide real-time and reliable patient data. This technological expertise not only sets Masimo apart from its competitors but also allows it to continuously introduce new and improved products to meet customer needs.

Secondly, Masimo has established a strong brand reputation as a trusted and reliable provider of medical devices. Healthcare professionals and hospitals have come to rely on Masimo's products for accurate and actionable data, enhancing patient care and improving outcomes. This brand recognition creates a competitive advantage for the company and increases customer loyalty.

Furthermore, Masimo has a global presence with distribution channels spanning across various regions. This extensive network enables the company to reach a diverse customer base and capitalize on opportunities in different markets.

Weaknesses

Despite its strengths, Masimo Corp also faces certain weaknesses that pose challenges to its growth. One weakness is the company's dependence on a limited number of key customers, which puts it at risk if any of these customers were to reduce their orders or switch to competitors. Diversifying the customer base would mitigate this risk.

Another weakness is the high research and development costs associated with developing and enhancing its innovative products. While this investment is necessary for staying ahead in the industry, it can strain the company's financial resources and profitability in the short term.

Opportunities

Masimo Corp operates in a healthcare industry that is constantly evolving and growing, presenting several opportunities for the company. One opportunity is the increasing adoption of remote patient monitoring and telehealth services, which are becoming more prevalent in healthcare systems worldwide. Masimo can leverage its technological expertise to develop solutions for these emerging trends, expanding its customer base and revenue streams.

Furthermore, the rising global healthcare expenditure provides a favorable market environment for Masimo. As governments and healthcare providers invest in improving patient care and outcomes, the demand for advanced medical monitoring technologies is expected to increase. By focusing on market penetration strategies and partnerships with healthcare organizations, Masimo can capitalize on this growing demand.

Threats

In addition to opportunities, Masimo Corp faces certain threats in its industry that must be addressed. One significant threat is the intense competition from other medical device companies. The market for medical monitoring technologies is highly competitive, and new entrants and existing competitors pose a risk to Masimo's market share.

Another threat is the regulatory environment for medical devices. Compliance with stringent regulations and obtaining necessary approvals can be time-consuming and costly. Changes in regulations or non-compliance could hinder Masimo's ability to bring products to market in a timely manner.

Lastly, economic downturns and fluctuations in healthcare spending can impact the demand for medical devices. A decrease in healthcare budgets or a slowdown in hospital investments could result in reduced demand for Masimo's products.

Masimo Segments

Masimo Eulerpool Fair Value

Masimo historical P/E ratio, EBIT multiple, and P/S ratio

Masimo annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Masimo shares outstanding

The number of shares was Masimo in 2025 — This indicates how many shares 53.6 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
52.8 M base_Shares
Jan 1, 2007
59.8 M base_Shares
Jan 1, 2008
60.2 M base_Shares
Jan 1, 2009
60.2 M base_Shares
Jan 1, 2010
60.6 M base_Shares
Jan 1, 2011
60.8 M base_Shares
Jan 1, 2012
58.4 M base_Shares
Jan 1, 2013
57.5 M base_Shares
Jan 1, 2014
55.6 M base_Shares
Jan 1, 2015
53.7 M base_Shares
Jan 1, 2016
53.2 M base_Shares
Jan 1, 2017
55.9 M base_Shares
Jan 1, 2018
56 M base_Shares
Jan 1, 2019
57.1 M base_Shares
Jan 1, 2020
58 M base_Shares

Masimo Dividend History

2 years of dividend payments

YearAnnual DividendYoY ChangePayments
20121USD 63.6%
20102.75USD

Masimo dividend payout ratio

In 2025, Masimo had a payout ratio of 138.1%. The payout ratio indicates the percentage of the company's profits that Masimo distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2006
160.37 %
Jan 1, 2007
160.37 %
Jan 1, 2008
160.37 %
Jan 1, 2009
160.37 %
Jan 1, 2010
227.27 %
Jan 1, 2011
160.37 %
Jan 1, 2012
93.46 %
Jan 1, 2013
160.37 %
Jan 1, 2014
138.06 %
Jan 1, 2015
130.63 %
Jan 1, 2016
143.02 %
Jan 1, 2017
137.24 %
Jan 1, 2018
136.96 %
Jan 1, 2019
139.07 %
Jan 1, 2020
137.76 %
Price targets and forecasts for Masimo are not yet available.

Masimo Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/4/20261.46USD406.06 MUSD2026 Q1
2/26/20261.51USD416.48 MUSD2025 Q4
5/7/20240.7USD526.4 MUSD2024 Q1
2/26/20240.81USD547.65 MUSD2023 Q4
8/7/20231.05USD579.77 MUSD2023 Q2
5/1/20230.95USD562.96 MUSD2023 Q1
2/13/20231.2USD611.53 MUSD2022 Q4
11/8/20220.94USD541.44 MUSD2022 Q3
8/9/20221.23USD548.67 MUSD2022 Q2
5/3/20220.89USD308.39 MUSD2022 Q1

EESG©

Eulerpool ESG Scorecard© for the Masimo stock

33/100
24
Environment
54
Social
22
Governance
E

Environment

20
Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees34
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Masimo shareholder structure

% Name
12.22151%
Fidelity Management & Research Company LLC
Fidelity Management & Research Company LLC
8.55715%
Politan Capital Management, L.P.
Politan Capital Management, L.P.
8.0927%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
7.95671%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
4.96057%
MFS Investment Management
MFS Investment Management
4.89146%
BlackRock Investment Management (UK) Ltd.
BlackRock Investment Management (UK) Ltd.
...

Masimo Executives and Management Board

MY

Mr. Micah Young

(46)

Chief Financial Officer, Executive Vice President

Compensation8.12 M USD
BT

Mr. Blair Tripodi

(51)

Chief Operating Officer - Consumer Division

Compensation6.85 M USD
MB

Ms. Michelle Brennan

(59)

Chairman of the Board · since 2023

Compensation1.97 M USD
QK

Mr. Quentin Koffey

(46)

Lead Independent Vice Chairman of the Board

Compensation300,889 USD
DS

Dr. Darlene Solomon

(66)

Independent Director

Compensation226,014 USD

Frequently asked questions about Masimo

The business model of Masimo Corp focuses on providing innovative noninvasive monitoring technologies. Masimo develops and manufactures a wide range of medical devices and sensors to improve patient outcomes and reduce healthcare costs. The company's flagship product, Masimo SET®, revolutionized pulse oximetry by offering accurate measurements even in challenging conditions. With a dedication to patient safety and care, Masimo Corp combines advanced signal processing and sensor technology to deliver reliable monitoring solutions to healthcare professionals. Through their product portfolio, Masimo Corp aims to enhance patient care and promote efficiency in the healthcare industry.

All fundamentals and in-depth analysis of Masimo

Our stock analysis for Masimo Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Masimo Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.